脂质体两性霉素 B 在胸腔积液中的药代动力学。
Pharmacokinetics of liposomal amphotericin B in pleural fluid.
机构信息
NIH Clinical Center Pharmacy Department, 10 Center Drive, Bethesda, MD 20892, USA.
出版信息
Antimicrob Agents Chemother. 2010 Apr;54(4):1633-5. doi: 10.1128/AAC.01438-09. Epub 2010 Jan 19.
Abstract
We report the penetration of liposomal amphotericin B into the pleural fluid of a patient with pulmonary zygomycosis and empyema. The ratio of area under the concentration-versus-time curve in pleural fluid (AUC(pleural fluid)) to that in serum (AUC(serum)) for liposomal amphotericin B over 24 h was 9.4%, with pleural fluid concentrations of 2.12 to 4.91 microg/ml. Given the relatively low level of intrapleural penetration of liposomal amphotericin B, chest tube drainage may be warranted for successful treatment of zygomycotic empyema.
摘要
我们报告了 1 例肺毛霉病并脓胸患者中脂质体两性霉素 B 进入胸腔液的情况。24 小时内脂质体两性霉素 B 的胸腔液 AUC（AUC（胸腔液））与血清 AUC（AUC（血清））的比值为 9.4%，胸腔液浓度为 2.12 至 4.91μg/ml。鉴于脂质体两性霉素 B 进入胸腔液的水平相对较低，可能需要胸腔引流管来成功治疗毛霉性脓胸。
相似文献
1
Pharmacokinetics of liposomal amphotericin B in pleural fluid.脂质体两性霉素 B 在胸腔积液中的药代动力学。
Antimicrob Agents Chemother. 2010 Apr;54(4):1633-5. doi: 10.1128/AAC.01438-09. Epub 2010 Jan 19.
2
Penetration of amphotericin B lipid formulations into pleural effusion.两性霉素B脂质制剂在胸腔积液中的渗透情况。
Antimicrob Agents Chemother. 2007 Nov;51(11):4211-3. doi: 10.1128/AAC.01087-07. Epub 2007 Sep 4.
3
Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate.静脉注射两性霉素B脂质体（安必素）和去氧胆酸盐两性霉素B后两性霉素B的血浆蛋白结合及结合型与游离型两性霉素B的药代动力学
Antimicrob Agents Chemother. 2002 Mar;46(3):834-40. doi: 10.1128/AAC.46.3.834-840.2002.
4
5
Use of nebulised liposomal amphotericin B in the treatment of Aspergillus fumigatus empyema.雾化脂质体两性霉素B在治疗烟曲霉脓胸中的应用。
Thorax. 1995 Dec;50(12):1321-3. doi: 10.1136/thx.50.12.1321.
6
[Pulmonary mucormycosis: benefit of aerosol amphotericin B?].[肺毛霉病：雾化两性霉素B的益处？]
Rev Mal Respir. 2001 Jun;18(3):309-13.
7
Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis.肺部毛霉病的鼠模型中两性霉素 B 脂质复合物与脂质体两性霉素 B 的比较药效学。
Antimicrob Agents Chemother. 2010 Mar;54(3):1298-304. doi: 10.1128/AAC.01222-09. Epub 2009 Dec 28.
8
Cunninghamella bertholletiae infection in a bone marrow transplant patient: amphotericin lung penetration, MIC determinations, and review of the literature.一名骨髓移植患者的柏氏小克银汉霉感染：两性霉素在肺部的渗透、最低抑菌浓度测定及文献综述
Pharmacotherapy. 2001 Jul;21(7):855-60. doi: 10.1592/phco.21.9.855.34560.
9
Adjuvant intrapleural amphotericin B therapy for pulmonary mucormycosis in a cardiac allograft recipient.心脏移植受者肺毛霉病的辅助性胸膜内两性霉素B治疗
Clin Transplant. 1997 Dec;11(6):608-12.
10
Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.两性霉素B脂质复合物与两性霉素B脂质体在急性侵袭性肺曲霉病小鼠模型中肺蓄积及真菌清除动力学的比较分析
Antimicrob Agents Chemother. 2007 Apr;51(4):1253-8. doi: 10.1128/AAC.01449-06. Epub 2007 Jan 29.
引用本文的文献
1
SARS-CoV-2 infection enhancement by amphotericin B: implications for disease management.两性霉素B增强严重急性呼吸综合征冠状病毒2感染：对疾病管理的启示
J Virol. 2025 Jul 22;99(7):e0051925. doi: 10.1128/jvi.00519-25. Epub 2025 Jun 4.
2
Disseminated fusariosis after allogenic hematopoietic stem cell transplantation: case report.异基因造血干细胞移植后播散性镰刀菌病：病例报告
Infection. 2025 Apr;53(2):727-731. doi: 10.1007/s15010-024-02376-w. Epub 2024 Aug 26.
3
Application and evaluation of topical amphotericin B for the treatment of respiratory fungal infections.局部用两性霉素B治疗呼吸道真菌感染的应用与评价
BMC Infect Dis. 2024 Apr 24;24(1):439. doi: 10.1186/s12879-024-09342-9.
4
The outcomes of thoracoscopic decortication between fungal empyema and bacterial empyema.胸腔镜下肺切除治疗真菌性脓胸和细菌性脓胸的疗效比较。
BMC Infect Dis. 2023 Jan 6;23(1):8. doi: 10.1186/s12879-022-07978-z.
5
A Case Report of -Associated Empyema Treated With Intravenous Injection and Local Thoracic Irrigation of Amphotericin B Plus Medical Thoracoscopy.一例 -相关脓胸经两性霉素 B 静脉注射和局部胸腔灌洗联合内科胸腔镜治疗。
Front Public Health. 2022 Jul 6;10:914529. doi: 10.3389/fpubh.2022.914529. eCollection 2022.
6
Systemic and Target-Site Pharmacokinetics of Antiparasitic Agents.抗寄生虫药物的全身和作用部位药代动力学。
Clin Pharmacokinet. 2020 Jul;59(7):827-847. doi: 10.1007/s40262-020-00871-5.
7
Characteristics of pulmonary mucormycosis and predictive risk factors for the outcome.肺部毛霉菌病的特征及预后的预测性风险因素。
Infection. 2018 Aug;46(4):503-512. doi: 10.1007/s15010-018-1149-x. Epub 2018 May 10.
8
Refractory bronchovascular pleuropulmonary mucormycosis: Case report and difficulties in management.难治性支气管血管性胸膜肺毛霉病：病例报告及管理难点
Lung India. 2018 Jan-Feb;35(1):70-72. doi: 10.4103/lungindia.lungindia_535_16.
9
Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.脂质体两性霉素B（安必素（®））：药代动力学、药效学、临床经验及未来方向综述
Drugs. 2016 Mar;76(4):485-500. doi: 10.1007/s40265-016-0538-7.
10
A 19-year-old woman with pleuritic chest pain.一名19岁伴有胸膜炎性胸痛的女性。
Can J Infect Dis Med Microbiol. 2015 Mar-Apr;26(2):100-2. doi: 10.1155/2015/652758.
本文引用的文献
1
Isolation and identification of Rhizomucor pusillus from pleural zygomycosis in an immunocompetent patient.从免疫功能正常患者的胸膜接合菌病中分离和鉴定微小根毛霉。
Med Mycol. 2009 Dec;47(8):869-73. doi: 10.3109/13693780903059485.
2
Recent advances in the management of mucormycosis: from bench to bedside.毛霉菌病治疗的最新进展：从实验室到临床
Clin Infect Dis. 2009 Jun 15;48(12):1743-51. doi: 10.1086/599105.
3
Successful treatment of pulmonary zygomycosis in two transplant recipients with liposomal amphotericin B and partial surgical resection followed by posaconazole.两名移植受者接受脂质体两性霉素B和部分手术切除治疗，随后使用泊沙康唑，成功治愈肺接合菌病。
Mycoses. 2010 Mar 1;53(2):163-7. doi: 10.1111/j.1439-0507.2008.01666.x. Epub 2009 Jan 9.
4
Levels of amphotericin B lipid formulations in ascites.两性霉素B脂质制剂在腹水中的水平。
J Antimicrob Chemother. 2008 Nov;62(5):1163-4. doi: 10.1093/jac/dkn306. Epub 2008 Jul 28.
5
Pulmonary zygomycosis.肺接合菌病
Semin Respir Crit Care Med. 2008 Apr;29(2):111-20. doi: 10.1055/s-2008-1063850.
6
Penetration of amphotericin B lipid formulations into pleural effusion.两性霉素B脂质制剂在胸腔积液中的渗透情况。
Antimicrob Agents Chemother. 2007 Nov;51(11):4211-3. doi: 10.1128/AAC.01087-07. Epub 2007 Sep 4.
7
Empyema thoracis due to Rhizopus oryzae in an allogenic bone marrow transplant recipient.一名同种异体骨髓移植受者因米根霉感染导致脓胸。
Med Mycol. 2006 Feb;44(1):75-8. doi: 10.1080/13693780500148392.
8
Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003).一家三级癌症中心血液系统恶性肿瘤患者的侵袭性真菌感染：一项为期15年（1989 - 2003年）的尸检研究
Haematologica. 2006 Jul;91(7):986-9. Epub 2006 Jun 1.
9
Epidemiology and outcome of zygomycosis: a review of 929 reported cases.毛霉菌病的流行病学与转归：929例报告病例的综述
Clin Infect Dis. 2005 Sep 1;41(5):634-53. doi: 10.1086/432579. Epub 2005 Jul 29.
10
Fatal course of pulmonary Absidia sp. infection in a 4-year-old girl undergoing treatment for acute lymphoblastic leukemia.一名正在接受急性淋巴细胞白血病治疗的4岁女孩肺部被犁头霉属真菌感染后的致命病程。
J Pediatr Hematol Oncol. 2005 Jul;27(7):386-8. doi: 10.1097/01.mph.0000171285.89950.00.
Zotero 插件